These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 26948676)
21. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice. Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847 [TBL] [Abstract][Full Text] [Related]
22. Fibrodysplasia ossificans progressiva with minor unilateral hallux anomaly in a sporadic case from Northern Tanzania with the common ACVR1c.617G>A mutation. Saleh M; Commandeur J; Bocciardi R; Kinabo G; Hamel B Pan Afr Med J; 2015; 22():299. PubMed ID: 26966495 [TBL] [Abstract][Full Text] [Related]
23. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva. Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359 [TBL] [Abstract][Full Text] [Related]
24. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report. Nakahara Y; Katagiri T; Ogata N; Haga N Am J Med Genet A; 2014 Jan; 164A(1):220-4. PubMed ID: 24259422 [TBL] [Abstract][Full Text] [Related]
25. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish. Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777 [TBL] [Abstract][Full Text] [Related]
27. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva]. Katagiri T; Kamizono J; Nakashima Y; Kitoh H; Susami T; Haga N Clin Calcium; 2010 Oct; 20(10):1510-7. PubMed ID: 20890033 [TBL] [Abstract][Full Text] [Related]
28. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease. Akyuz G; Gencer-Atalay K; Ata P Curr Opin Pediatr; 2019 Dec; 31(6):716-722. PubMed ID: 31693578 [TBL] [Abstract][Full Text] [Related]
29. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva. Katagiri T; Tsukamoto S; Kuratani M Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575 [TBL] [Abstract][Full Text] [Related]
30. ACVR1 Function in Health and Disease. Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F Cells; 2019 Oct; 8(11):. PubMed ID: 31683698 [No Abstract] [Full Text] [Related]
31. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1. Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272 [TBL] [Abstract][Full Text] [Related]
32. Fibrodysplasia Ossificans Progressiva: A Case Report with Pseudo-Ankylosis of the Temporomandibular Joint. Chaisrisawadisuk S; Oliver KJ; Constantine S; Azzopardi J; Anderson PJ; Moore MH Cleft Palate Craniofac J; 2024 May; 61(5):897-900. PubMed ID: 36536588 [TBL] [Abstract][Full Text] [Related]
33. Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice. Yamamoto R; Matsushita M; Kitoh H; Masuda A; Ito M; Katagiri T; Kawai T; Ishiguro N; Ohno K J Bone Miner Metab; 2013 Jan; 31(1):26-33. PubMed ID: 23011467 [TBL] [Abstract][Full Text] [Related]
34. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)]. Katagiri T Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931 [TBL] [Abstract][Full Text] [Related]